Design of Targeted B Cell Killing Agents
Open Access
- 6 June 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6), e20991
- https://doi.org/10.1371/journal.pone.0020991
Abstract
B cells play an important role in the pathogenesis of both systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce autoantibodies, but also are capable to efficiently present specific autoantigens to T cells. Furthermore, B cells can secrete proinflammatory cytokines and amplify the vicious process of self-destruction. B cell-directed therapy is a potentially important approach for treatment of various autoimmune diseases. The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab® used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved. In this study we designed a repertoire of genetically engineered B cell killers that specifically affected one kind of cells carrying a respective B cell receptor. We constructed immunotoxins (ITs), fused with c-myc epitope as a model targeting sequence, based on barnase, Pseudomonas toxin, Shiga-like toxin E.coli and Fc domain of human antibody IgGγ1. C-MYC hybridoma cell line producing anti-c-myc IgG was chosen as a model for targeted cell depletion. C-myc sequence fused with toxins provided addressed delivery of the toxic agent to the target cells. We demonstrated functional activity of designed ITs in vitro and showed recognition of the fusion molecules by antibodies produced by targeted hybridoma. To study specificity of the proposed B cells killing molecules, we tested a set of created ITs ex vivo, using C-MYC and irrelevant hybridoma cell lines. Pseudomonas-containing IT showed one of the highest cytotoxic effects on the model cells, however, possessed promiscuous specificity. Shiga-like toxin construct demonstrated mild both cytotoxicity and specificity. Barnase and Fc-containing ITs revealed excellent balance between their legibility and toxic properties. Moreover, barnase and Fc molecules fused with c-myc epitope were able to selectively deplete c-myc-specific B cells and decrease production of anti-c-myc antibodies in culture of native splenocytes, suggesting their highest therapeutic potential as targeted B cell killing agents.Keywords
This publication has 48 references indexed in Scilit:
- Shiga toxin and its use in targeted cancer therapy and imagingMicrobial Biotechnology, 2010
- An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivoMolecular Cancer, 2010
- Catalytic antibodies: balancing between Dr. Jekyll and Mr. HydeBioEssays, 2009
- Differential contribution of the m7G-cap to the 5′ end-dependent translation initiation of mammalian mRNAsNucleic Acids Research, 2009
- Efficient cap-dependent translation of mammalian mRNAs with long and highly structured 5′-untranslated regions in vitro and in vivoMolecular Biology, 2009
- Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progressionJCI Insight, 2008
- Barnase as a New Therapeutic Agent Triggering Apoptosis in Human Cancer CellsPLOS ONE, 2008
- Regulatory role of B-1 B cells in chronic colitisInternational Immunology, 2008
- The ‘short’ history of regulatory B cellsTrends in Immunology, 2008
- Immunotoxins for targeted cancer therapyThe AAPS Journal, 2006